Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) (PXS-X02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00235482
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : June 27, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.

Condition or disease Intervention/treatment Phase
Malignant Melanoma Drug: Coxsackievirus A21 Phase 1

Detailed Description:
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Intervention Model Description: CAVATAK
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
Actual Study Start Date : November 8, 2005
Actual Primary Completion Date : April 21, 2006
Actual Study Completion Date : April 21, 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Primary Outcome Measures :
  1. Safety profile of treatment, characterisation of adverse events

Secondary Outcome Measures :
  1. Efficacy - clinical response of injected and non-injected tumours

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • stage IV melanoma (AJCC classification)
  • minimum of 2 sc metastases
  • failure or refusal of standard chemotherapy
  • ECOG score of 0 or 1
  • other

Exclusion Criteria:

  • metastatic CNS disease
  • ocular or mucosal melanoma
  • immunodeficiency
  • splenectomy
  • other

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00235482

Layout table for location information
Australia, New South Wales
Melanoma Unit, Mater Misericordiae Hospital
Newcastle, New South Wales, Australia, 2298
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Viralytics Identifier: NCT00235482    
Other Study ID Numbers: V937-002
PSX-X02 ( Other Identifier: Viralytics Study ID )
First Posted: October 10, 2005    Key Record Dates
Last Update Posted: June 27, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Coxsackievirus Infections
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Virus Diseases